Skip to Content

'
Michael S. Ewer, MD, MPH, JD, LLM, MBA

Present Title & Affiliation

Primary Appointment

Special Assistant to the Vice President of Medical Affairs, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Division of Internal Medicine, University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, TX

Education & Training

Degree-Granting Education

2005 University of Houston Law Center, Houston, TX, LLM, Master of Law
2001 University of Houston Law Center, Houston, TX, JD, Doctor of Jurisprudence
1989 University of Texas, School of Public Health, Houston, TX, MPH, Master of Public Health
1969 University of Basel, Basel, Switzerland, MD, Medicine

Board Certifications

1980 American Board of Internal Medicine

Selected Publications

Peer-Reviewed Original Research Articles
1. Ewer MS, Glück S. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer 115(9):1813-26, 5/1/2009. e-Pub 2/2009. PMID: 19235248.
2. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13(1):228-33, 1/1/2007. PMID: 17200359.
3. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf 5(6):791-809, 11/2006. PMID: 17044806.
4. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther 6(9):1249-69, 9/2006. PMID: 17020459.
5. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23(31):7820-6, 11/1/2005. PMID: 16258084.
6. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23(13):2900-2, 5/1/2005. PMID: 15860848.
7. Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA. Cardiac safety of liposomal anthracyclines. Semin Oncol 31(6 Suppl 13):161-81, 12/2004. PMID: 15717742.

Abstracts
1. Monnier A, Ewer MS. Update on the cardiovascular safety of aromatase inhibitors. IMPAKT Breast Cancer Conference, May 709, 2009, Brussels, Belgium(abstract #76P) (#76P), 5/2009.

Last updated: 12/21/2012